Haixi New Drug adopts a dualtrack model of generic drugs + innovative drugs. Currently, the company has generic drugs approved by the National Medical Products Administration, and there are innovative drugs in the pipeline.
Haixi Pharmaceutical 's commercialized product portfolio mainly includes generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases; according to data from Frost & Sullivan, these therapeutic areas account for more than % of China's total pharmaceutical sales in .
Among the generic drugs approved by the National Medical Products kazakhstan phone number list Administration, four have been selected for the national volumebased procurement plan marked in red below. In addition, there are four generic drugs under development in the ANDA stage for epilepsy, allergies, hypertension and electrolyte supplementation, which are expected to be approved for marketing in .
Among them, Anbili, Ruantuo and Haihuitong are the main sources of revenue. From January to September , the sales revenue of the three products accounted for more than %.
As for the four innovative drugs under development, their indications range from oncology to ophthalmology and other different fields.